Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients.

BACKGROUND Tissue accumulation of advanced glycation end-products (AGE) is thought to be a contributing factor to the progression of cardiovascular disease (CVD). Skin autofluorescence, a non-invasive measure of AGE accumulation using autofluorescence of the skin under ultraviolet light, has shown associations with CVD in haemodialysis patients. The present study aimed to evaluate relationships of skin autofluorescence to renal function as well as CVD in pre-dialysis patients with chronic kidney disease (CKD). METHODS Subjects in this cross-sectional analysis comprised 304 pre-dialysis CKD patients [median age, 62.0 years; median estimated glomerular filtration rate (eGFR), 54.3 mL/min/1.73 m(2); diabetes, n = 81 (26.6%)]. AGE accumulation in skin was assessed by skin autofluorescence using an autofluorescence reader. Relationships between skin autofluorescence, eGFR, CVD history and other parameters were evaluated. RESULTS Skin autofluorescence correlated negatively with eGFR (r = -0.42, P < 0.01) and increased as CKD stage advanced. Multiple regression analysis revealed significant correlations of skin autofluorescence with age, presence of diabetes, eGFR and CVD history in CKD patients (R(2) = 30%). Age, male gender, smoking history, skin autofluorescence and eGFR were significantly correlated with CVD history, and multiple logistic regression analysis identified age [odds ratio (OR), 1.09; 95% confidence interval (CI), 1.03-1.15; P < 0.01], history of smoking (OR, 6.50; 95%CI, 1.94-21.83; P < 0.01) and skin autofluorescence (OR, 3.74; 95%CI, 1.54-9.24; P < 0.01) as independent factors. CONCLUSIONS Tissue AGE accumulation measured as skin autofluorescence increased as GFR decreased and was related to CVD history in CKD patients. Non-invasive autofluorescence readers may provide potential markers for clinical risk assessment in pre-dialysis CKD patients.

[1]  M. Jadoul,et al.  Preparing renal replacement therapy in stage 4 CKD patients referred to nephrologists: a difficult balance between futility and insufficiency. A cohort study of 386 patients followed in Brussels. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  T. Hashimoto,et al.  Advanced glycation end products in nondiabetic patients with coronary artery disease. , 2001, Diabetes care.

[3]  R. Foley,et al.  Epidemiology of cardiovascular disease in chronic renal disease , 2000 .

[4]  D. Levy,et al.  Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. , 1999, Kidney international.

[5]  D. Hricik,et al.  Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. , 1996, Clinical transplantation.

[6]  T. Miyata,et al.  Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods , 2007, Rheumatology International.

[7]  E. Friedman,et al.  Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.

[8]  U. Ott,et al.  Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. , 2004, Kidney international.

[9]  C van Ypersele de Strihou,et al.  Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. , 1996, Journal of the American Society of Nephrology : JASN.

[10]  T. Miyata,et al.  Relationship of Skin Autofluorescence to Cardiovascular Disease in Japanese Hemodialysis Patients , 2009, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[11]  H. Wulf,et al.  Autofluorescence of human skin is age-related after correction for skin pigmentation and redness. , 2001, The Journal of investigative dermatology.

[12]  M. Nangaku,et al.  Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.

[13]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  A. Smit,et al.  Simple Noninvasive Measurement of Skin Autofluorescence , 2005, Annals of the New York Academy of Sciences.

[15]  A. Smit,et al.  A tool to identify type 2 diabetic patients at risk for developing microvascular complications , 2008 .

[16]  Kdoqi Disclaimer K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  C. Wanner,et al.  Advanced glycation end products and mortality in hemodialysis patients. , 2002, Kidney international.

[18]  T. Miyata,et al.  Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. , 1998, Journal of the American Society of Nephrology : JASN.

[19]  R. Petersen,et al.  Clinical Subtypes of Alzheimer’s Disease , 1998, Dementia and Geriatric Cognitive Disorders.

[20]  T. Miyata,et al.  Advanced glycation end products in patients with cerebral infarction. , 2009, Internal medicine.

[21]  S. Devaraj,et al.  Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease , 2002, Current opinion in nephrology and hypertension.

[22]  Reindert Graaff,et al.  Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[23]  R. Gans,et al.  Simple non-invasive assessment of advanced glycation endproduct accumulation , 2004, Diabetologia.

[24]  N. Powe,et al.  Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. , 2002, Journal of the American Society of Nephrology : JASN.

[25]  S. Fukumoto,et al.  Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. , 2008, Metabolism: clinical and experimental.

[26]  T. Miyata,et al.  Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.

[27]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[29]  A. Smit,et al.  AGEs, autofluorescence and renal function. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  C. Elmets,et al.  Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. , 1986, The New England journal of medicine.

[31]  T. Miyata,et al.  Carbonyl Stress: Increased Carbonyl Modification of Proteins by Autoxidation Products of Carbohydrates and Lipids in Uremia , 1999, The International journal of artificial organs.

[32]  C. Gullion,et al.  Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. , 2004, Archives of internal medicine.

[33]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.